VP
PBLS

venBio Partners’s Parabilis Medicines Inc PBLS Stock Holding History

venBio Partners’s Portfolio PBLS Stock Details PBLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$144M Buy
+5,266,697
New +$145M 27.75% 2

Other funds holding PBLS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
JTL
Jupiter Topco LLC New York $245B AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

venBio Partners's PBLS Position: Q2 2026 in Review

venBio Partners opened a new position in Parabilis Medicines Inc (PBLS) in Q2 2026: 5,266,697 shares worth $144M. The stake represents 27.75% of the portfolio and ranks #2 among its holdings.

68 funds tracked by Wall St. Rank hold PBLS as of Q2 2026.

  • venBio Partners held 5,266,697 shares of Parabilis Medicines Inc worth $144M as of Q2 2026.
  • Parabilis Medicines Inc was a new venBio Partners position in Q2 2026.
  • Parabilis Medicines Inc made up 27.75% of venBio Partners's portfolio in Q2 2026, its #2 holding.
  • 68 funds tracked by Wall St. Rank held Parabilis Medicines Inc as of Q2 2026.

Based on venBio Partners's 13F filing for Q2 2026, filed 14 Aug 2026.